NAD+ vs NMN vs NR: The Precursor Pathway, Read Carefully
NAD+ is a central metabolic cofactor whose tissue concentrations decline with age. NMN and NR are the two oral precursors competing for the supplement market. The biology is real; the precursor comparison is more contested than the marketing suggests.
approximate decline in tissue NAD+ levels observed between young and old adults in some tissue studies.
both NMN and NR are absorbed orally; NAD+ itself is not orally bioavailable in meaningful amounts.
the proposed dedicated NMN transporter, the subject of significant scientific controversy.
NAD+ is a required cofactor for sirtuin and PARP enzyme classes.
NAD+ (nicotinamide adenine dinucleotide) is a central cofactor in energy metabolism, sirtuin activity and DNA repair. Tissue NAD+ declines with age. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are oral precursors that raise systemic NAD+ availability. The choice between them turns on disputed pharmacology (the Slc12a8 transporter story) and on whose trial data you read. Both raise blood NAD+; clinical-outcome benefit in healthy ageing humans remains the open question.
Raising blood NAD+ is settled science. Translating that into a clinical longevity benefit in healthy humans is not.
What they are
NAD+ is nicotinamide adenine dinucleotide, a small-molecule cofactor required by sirtuins (SIRT1-7), PARPs and CD38 — all enzymes implicated in metabolism, DNA repair and ageing biology. Tissue NAD+ levels decline with age in multiple species.
NMN (nicotinamide mononucleotide) is one biosynthetic step closer to NAD+ than nicotinamide. NR (nicotinamide riboside) is one step further upstream. Both are absorbed orally and raise systemic NAD+ availability in published pharmacokinetic studies.
The 'which is better' debate turns on transport pharmacology. Imai's group described Slc12a8 as a dedicated intestinal NMN transporter; Brenner's group has disputed this. The empirical question of which precursor raises NAD+ more efficiently in which tissues is unsettled.
The precursor question
| Layer | What the research describes |
|---|---|
| NAD+ | Not orally bioavailable in meaningful amounts; injectable forms exist but precursor route dominates supplementation. |
| NMN | One biosynthetic step from NAD+; Imai group reports dedicated Slc12a8 intestinal transporter; clinical PK supports oral absorption. |
| NR | Further upstream precursor; Brenner group reports superior efficiency; FDA-recognised as new dietary ingredient (US). |
| Salvage pathway | Both precursors enter the NAD+ salvage pathway via NAMPT or NMNAT enzymes. |
| Tissue distribution | Different tissue compartments may be raised differentially by the two precursors; head-to-head trial data are limited. |
The precursor wars are partly scientific, partly commercial. The clinical-endpoint question — does raising NAD+ extend healthspan in humans — is the same regardless of which precursor is used.
Clinical trial evidence
Blood NAD+ elevation
Both NMN and NR consistently raise blood NAD+ in pharmacokinetic and short-term trials. This is settled.
Clinical endpoints
Trials in cardiometabolic markers, insulin sensitivity and functional outcomes have shown mixed and modest results; large definitive longevity trials in healthy adults are absent.
Disease-state trials
Several small trials in specific conditions (e.g., progressive disease populations) show variable benefit signals; populations and endpoints differ.
The honest position is that NAD+ biology is real and important, oral precursors do raise NAD+, and the clinical-outcome translation in healthy adults remains the open question. The supplement market has run far ahead of the trial evidence on healthspan endpoints.
This is not a criticism — early-stage interventions in a foundational pathway are scientifically interesting. It is a calibration: the mechanism is strong, the human clinical outcomes evidence is thinner.
What we know, what's still open
- NAD+ decline with age: Well-established across multiple tissue studies.
- Oral precursors raise NAD+: Settled in pharmacokinetic trials.
- NMN vs NR superiority: Contested; depends on tissue, transporter biology and trial design.
- Healthy-adult longevity benefit: Open question — no large definitive RCTs at lifespan endpoints.
- Disease-state benefit: Mixed signals across small trials; varies by indication.
Frequently asked
Should I take NMN or NR?
Both raise NAD+; the head-to-head superiority question is not cleanly answered by current evidence. Clinical-outcome differences in healthy adults have not been demonstrated.
Does it actually slow ageing?
Mechanistically plausible. Clinically, definitive healthspan or lifespan trials in humans are absent.
What about IV NAD+?
Injectable NAD+ raises blood levels acutely; mechanism for benefit beyond oral precursors is debated. Trial evidence at clinical-outcome endpoints is limited.
Is it safe?
Short-term safety in healthy adults appears favourable across trials; long-term safety in chronic supplementation is still accumulating.
Where to read further
- • Imai S, Guarente L. NAD+ and sirtuins in ageing and disease. Trends Cell Biol 2014.
- • Mills KF et al. Long-term oral NMN administration in mice. Cell Metab 2016.
- • Martens CR et al. NR safety and pharmacokinetics in healthy adults. Nat Commun 2018.